United States: Delaware Court Of Chancery Rules Reverse Triangular Mergers Do Not Result In Assignments By Operation Of Law

In an opinion published on March 8, 2013, the Delaware Court of Chancery ruled in Meso Scale Diagnostics v. Roche Diagnostics, C.A. No. 5589-VCP (Mar. 8, 2013) that a reverse triangular merger does not result in an assignment of the assets of the surviving entity, by operation of law or otherwise. Although this decision confirms long-held views of generations of corporate lawyers, it reverses a previous holding from April 2011 in this same case and contradicts two previous Federal District Court opinions interpreting California and New Jersey law.

This case of first impression in Delaware, the most important jurisdiction for U.S. corporate law, will likely be viewed with relief by corporate practitioners because it both resolves the ambiguity created by that earlier ruling in this same case and because it sits in stark conflict with two previous Federal District Court opinions: a much-debated, unpublished 1991 opinion of the United States District Court for the Northern District of California in SQL Solutions, Inc. v. Oracle Corp., 1991 WL 626458 (N.D. Cal. Dec. 18, 1991) and a 2012 opinion of the United States District Court for the District of New Jersey in DBA Distribution Services, Inc. v. All Source Freight Solutions, Inc., 2012 WL 845929 (D.N.J. Mar. 13, 2012). Each of these prior cases, which found the question to be one of first impression under the laws of California and New Jersey, respectively, held that a reverse triangular merger transferred a license by operation of law in violation of the anti-assignment provisions in the licenses in question. In declining to follow SQL Solutions, Vice Chancellor Parsons asserted that such a view would frustrate the parties' intentions and conflict with Delaware jurisprudence on the effects of stock acquisitions.

Facts and Procedural History

The dispute at issue in this case stems from a series of agreements relating to the use of electrochemiluminescent ("ECL") technology, which is a sophisticated diagnostic and assay technology used in drug research and human diagnostics. In 2003, defendant Roche Diagnostics GmbH, C.A. ("Roche") received a new, field-limited, non-exclusive license to this ECL Technology after breaching and subsequently losing a license it had previously held to this technology. This license was granted in conjunction with the transfer of the ECL Technology patent rights to the newly formed BioVeris Corporation ("BioVeris"). Plaintiffs Meso Scale Diagnostics, LLC and Meso Scale Technologies, LLC (together, "Meso Scale"), which are the exclusive licensee under the ECL Technology for all other fields, consented to and "joined" this license agreement. This new license included an anti-assignment provision, which stated: "Neither this Agreement nor any of the rights, interests or obligations under [it] shall be assigned, in whole or in part, by operation of law or otherwise by any of the parties without the prior written consent of the other parties." The license did not include a change of control provision; however, which clause would have resolved the matter at issue in this case unambiguously.

In response to a dispute in 2007 regarding whether Roche's use of the ECL technology had again exceeded the field of its limited license, Roche acquired BioVeris through a reverse triangular merger, with BioVeris surviving as a wholly owned subsidiary. On June 22, 2010, Meso Scale sued Roche on two counts: (1) that the reverse triangular merger was an assignment by operation of law that required its consent and (2) that Roche breached the 2003 license by exceeding the field limitation of its limited license to the ECL technology, which license Meso Scale could enforce as a "joined" party (the licensor having received $600 million in cash as part of the acquisition and becoming a subsidiary of Roche no longer objected to Roche's potential breach).

Roche moved to dismiss Meso Scale's complaint, arguing, among other things, that the completed reverse triangular merger had only changed the ownership of BioVeris and not the entity itself, and therefore no assignment of the license had occurred in violation of this anti-assignment provision. In denying Roche's motion, Vice Chancellor Parsons ruled in Meso Scale Diagnostics v. Roche Diagnostics GMBH, 2011 WL 1348438 (Del. Ch. Apr. 8, 2011) that, for purposes of a motion to dismiss in a case of first impression under Delaware law, Meso Scale's interpretation of the anti-assignment provision was not unreasonable. Vice Chancellor Parsons also observed that Roche's post-acquisition behavior, where it transformed BioVeris into little more than an intellectual property holding company by discontinuing all of Bioveris' products, firing all its employees and closing its facility within months of the merger, hurt Roche's argument that all that had really occurred was a change of ownership.

Holding and Reasoning

Following discovery, Roche moved for summary judgment on both counts of Meso Scale's complaint. The Delaware Court of Chancery granted Roche's motion with respect to the first count, ruling that the reverse triangular merger was not an assignment by operation of law or otherwise and therefore did not trigger the anti-assignment provision in the 2003 license agreement that required Meso Scale's consent. Vice Chancellor Parsons began by noting that there is no Delaware case law that directly addresses whether a reverse triangular merger can be viewed as an assignment by operation of law or otherwise, before reviewing the provisions of Delaware's General Corporation Law and both contractual and legal theory as adopted in Delaware to reach the conclusion that it should not.

Turning first to Delaware law, Vice Chancellor Parsons observed that Delaware General Corporation Law, Title 8, Section 259(a), and its interpreting case law, hold that a merger or consolidation results in the transfer of the non-surviving corporation's rights and obligations to the surviving corporation, which is consistent with the interpretation of commentators that no transfer of the surviving entity's rights or obligations occurs in a reverse triangular merger. This same consensus, when viewed by the Vice Chancellor using the objective theory of contract interpretation that is followed in Delaware, makes it unlikely the parties would have expected a clause covering assignments to apply in the context of a reverse triangular merger. Meso Scale's next argument, that the acquisition of BioVeris resulted, practically, in nothing more than an assignment of the intellectual property rights of BioVeris to Roche, was rejected by the court under the doctrine of independent legal significance, wherein acts taken under different sections of the Delaware General Corporation Law are acts of independent legal significance even though the end result may be the same as the result of actions taken under a different section. Finally, the Vice Chancellor rejected Meso Scale's argument that the court should look to Delaware case law on forward triangular mergers, noting that in mergers of that form the target company does not survive the transaction as it does in the reverse triangular context.

The Delaware Court of Chancery, however, denied Roche's motion for summary judgment with respect to the second count, holding that Meso Scale had raised a triable issue of material fact as to whether it was a party to, and so could enforce, the 2003 license and with it the field restriction. Trial as to this count began on March 1, 2013, and a decision is expected presently.


The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions